Introduction
============

Two prominent members of the transient receptor potential (TRP) family, the vanilloid subtype-1 (TRPV1) receptor and the ankyrin subtype-1 (TRPA1) receptor are extensively coexpressed in peripheral sensory neurons and function as sensory transducers of noxious stimuli (Caterina et al. [@b9]; Palazzo et al. [@b26]). The relative sensitivity of these receptors to their respective agonists can have a major impact on nociceptive signaling in health and disease. Several chemical agents are capable of acutely sensitizing TRPV1 receptors to thermal mediators resulting in the sensation of pain (Lu et al. [@b19]; Novakova-Tousova et al. [@b25]; Holzer [@b14]; Wang [@b35]), whereas desensitization of the receptor via repetitive stimulation plays an important role in blocking pain transmission (Mandadi et al. [@b20]; Larrucea et al. [@b15]). Recent evidence has suggested that cross talk between TRPV1 and TRPA1 receptors may serve to integrate distinct nociceptive signaling pathways and provide a novel mechanism for integration of nociceptive information (Akopian et al. [@b2], [@b3]; Ruparel et al. [@b30]; Salas et al. [@b31]). Little is known about the cellular signaling pathways by which TRPV1 and TRPA1 channels communicate with each other in sensory neurons.

Propofol is one of the most commonly used intravenous anesthetics for the induction and maintenance of general anesthesia and sedation. Apart from its anesthetic properties, propofol has several nonanesthetic effects, one of which is the activation of TRPA1 ion channels to enhance pain and inflammation (Matta et al. [@b22]). Our laboratory has recently shown that propofol restores the sensitivity of TRPV1 receptors following agonist-induced desensitization via a TRPA1 dependent pathway in mouse dorsal root ganglion (DRG) sensory neurons (Zhang et al. [@b38]). Moreover, we also demonstrated in an earlier study that the propofol-induced restoration of TRPV1 sensitivity occurs via a protein kinase C epsilon (PKC*ε*)-dependent phosphorylation of the TRPV1 receptor (Wickley et al. [@b36]). The extent to which the actions of propofol on TRPA1 and PKC*ε* signaling pathways operate independently in parallel or are directly linked has not been determined. Moreover, the mechanism by which TRPA1 activation stimulates PKC*ε* autophosphorylation and activation is also not known. We rationalized that activation of nitric oxide synthase (NOS) and production of nitric oxide (NO) following TRPA1 stimulation may play a role in mediating PKC*ε* activation, at least in part, since TRPA1 activation has been associated with NO production in human lung carcinoma cells (Sun et al., [@b135]) and NO selectively activates PKC*ε* in isolated adult rabbit hearts (Ping et al. [@b27]). Therefore, our objectives were to confirm that TRPA1 activation directly results in PKC*ε* activation and to elucidate the cellular mechanism by which this occurs.

In the current study, we tested the hypothesis that inhibition of PKC*ε* attenuates the restoration of TRPV1 sensitivity induced by the TRPA1 agonists, allyl isothiocyanate (AITC) and the general anesthetic, propofol. Moreover, we also tested the hypothesis that the presence of TRPA1 receptors is required for the propofol- and AITC-induced activation of PKC*ε* as well as subsequent phosphorylation of TRPV1 receptors. Finally, we tested the hypothesis that TRPA1-dependent activation of NOS and NO production are involved in the autophosphorylation/activation of PKC*ε* and restoration of TRPV1 sensitivity to agonist stimulation.

Materials and Methods
=====================

F-11 cell transfection with TRPV1 or TRPA1 cDNA
-----------------------------------------------

Cultured F-11 cells (DRG-like hybridoma cell line) were transfected with TRPV1 or TRPA1 cDNA via electroporation using the Neon Transfection System (Invitrogen, Carlsbad, CA) as per the manufacturer's instructions for F-11 cells. Briefly, cultured F-11 cells at 80% confluence were harvested and washed with phosphate-buffered saline (PBS) without Ca^2+^ or Mg^2+^. The cells were resuspended in 100 *μ*L of electrolytic Buffer R in a sterile eppendorf tube and 5 *μ*g of either TRPV1 or TRPA1 cDNA was then added. Electroporation was performed using a pulse voltage of 1500 V, a pulse width of 35 msec and a pulse number of 2. Following electroporation, the cells were then suspended in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum at 37°C. A proportion of the cells were seeded onto coverslips in 6-well dishes and used for intracellular Ca^2+^ measurements, while the remainder were used for immunoblot analysis to confirm the presence and/or absence of TRPV1 and TRPA1.

Intracellular Ca^2+^ measurements
---------------------------------

F-11 cells were incubated at room temperature (23°C) for 15 min with fura-2 acetoxy methylester (fura-2/AM; 2 *μ*mol/L) in HEPES-buffered (2-\[4-(2-hydroxyethyl)piperazin-1-yl\]ethanesulfonic acid saline containing the following: 118 mmol/L NaCl, 4.8 mmol/L KCl, 1.2 mmol/L MgCl~2~, 1.25 mmol/L CaCl~2~, 11.0 mmol/L dextrose, 5 mmol/L pyruvate, and 25 mmol/L HEPES (pH 7.35). Coverslips containing the fura-2-loaded F-11 cells were placed in a temperature-regulated (30°C) chamber (Warner Instruments, Hamden, CT) mounted on the stage of an Olympus IX-81 inverted fluorescence microscope (Olympus America, Lake Success, NY). The cells were superfused continuously with HEPES-buffered saline at a flow rate of 2 mL/min. Drugs were delivered by switching from control buffer to drug-containing buffer for 20 sec unless noted otherwise. Intracellular free Ca^2+^ concentration (\[Ca^2+^\]~i~) measurements were simultaneously performed on multiple individual cells using a fluorescence imaging system (Easy Ratio Pro, Photon Technology International, Lawrenceville, NJ) equipped with a multi-wavelength spectrofluorometer (DeltaRAM X) and a QuantEM 512SC electron multiplying charge-coupled device camera (Photometrics, Tuscon, AZ). Images and photometric data were acquired by alternating excitation wavelengths between 340 and 380 nm (20 Hz) and monitoring an emission wavelength of 510 nm. Due to the fact that calibration procedures rely on a number of assumptions, the ratio of the light intensities at the two wavelengths was used to measure qualitative changes in \[Ca^2+^\]~i~. Just before data acquisition, background fluorescence was measured and automatically subtracted from the subsequent experimental measurement using Easy Ratio Pro.

Immunoblot analysis of PKC*ε*, TRPV1, and nNOS (total and phosphorylated)
-------------------------------------------------------------------------

Immunoblot analysis was carried out on whole F-11 cell lysates (Zhang et al. [@b38]). Protein concentration was assessed using the Bradford method (Bradford [@b6]). All samples were adjusted to a protein concentration of 1--2 mg/mL in sample buffer, boiled for 5 min, and then kept at −20°C until use. Equal amounts of protein (50 *μ*g) were separated by SDS-PAGE on 12% polyacrylamide gels and transferred to nitrocellulose membranes. Nonspecific binding was blocked with Tris-buffered saline solution (0.1% \[vol/vol\] Tween-20 in 20 mmol/L Tris base, 137 mmol/L NaCl adjusted to pH 7.6 with HCl, containing 3% \[wt/vol\] bovine serum albumin for 1 h at room temperature. Monoclonal antibodies against total PKC*ε* (BD Transduction Laboratory, 1 Becton Drive, Franklin Lakes, NJ, 07417, USA) and polyclonal antibodies against serine 729 phosphorylated PKC*ε* (Invitrogen, 5791 Van Alley Way, Carlsbad, CA 92008, USA), TRPV1 (Santa Cruz Biotechnology, 10410 Finnell Street, Dallas, TX, 75220, USA), serine 800 phosphorylated TRPV1 (Gift from Dr. Tominaga), serine 1417 phosphorylated nNOS (Abcam, 1 Kendall Square, Suite B2304, Cambridge, MA 02139, USA) or nNOS (Cell Signaling, 32 Tozer Road, Beverly MA, 01915, USA) were diluted 1:1000 in Tris-buffered saline containing 1% bovine serum albumin for immunoblotting (2 h). After washing in Tris-buffered saline three times (10 min each), membranes were incubated for 1 h at room temperature with horseradish-peroxidase-linked secondary antibody (goat anti-mouse and goat anti-rabbit; 1:5000 dilution in Tris-buffered saline containing 1% bovine serum albumin). Membranes were again washed and bound antibody was detected by enhanced chemiluminescence. Immunoreactivity was quantified by scanning densitometry and analyzed using software (ImageJ; National Institutes of Health, Washington, DC).

Selection criteria for determining subpopulations of transfected F-11 neurons
-----------------------------------------------------------------------------

F-11 cells (Platika et al. [@b28]) that either transfected with only TRPV1 receptors or both TRPV1 and TRPA1 receptors were first identified by treating the cells with single applications of capsaicin and AITC. Cells responsive to only capsaicin were deemed to contain only functional TRPV1 receptors, while cells that were responsive to capsaicin and AITC were deemed to contain both TRPV1 and TRPA1 receptors. Cells that did not respond to capsaicin or AITC were excluded from the study and therefore were not used in the statistical analysis.

Measurement of NO production in TRPV1-TRPA1 cotransfected F-11 cells and fluorescence microscopy
------------------------------------------------------------------------------------------------

NO detection kit for fluorescence microscopy was purchased from ENZO Life Sciences (10 Executive Boulevard, Farmingdale, NY, 11735, USA). All reagents were diluted in accordance to the product instructions. Cells were seeded the day before the experiment to ensure 50--70% confluency on the day of the experiment and were cultured in [l]{.smallcaps}-Arginine free media. On the day of the experiment, cells were pretreated with the NO scavenger c-PTIO and incubated with the NO detection reagent for 2 h. Cells were washed twice with wash buffer and then treated with experimental test agents including propofol (10 *μ*mol/L), AITC (100 *μ*mol/L), SNAP (100 *μ*mol/L), and HC-030031 (0.5 *μ*mol/L). Cells were treated with the NO-inducer, [l]{.smallcaps}-Arginine (100 *μ*mol/L) and the NO-scavenger, 2-4-carboxyphenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (c-PTIO;10 *μ*mol/L) as positive and negative controls, respectively. Posttreatment, cells were rinsed with wash buffer and examined under a fluorescence/confocal microscope (Olympus IX-70, FV5 PSU, Olympus America, 3500 Corporate Parkway, Center Valley, PA, 18034, USA) using the filter set Cyanine 5 (650/670 nm).

Composition of propofol
-----------------------

The Diprivan® lipid emulsion form of propofol (56 mmol/L \[10 mg/mL\] propofol, 10% soybean oil, 2.25% glycerol, 1.2% purified phospholipid) was used in all protocols and will be referred to as propofol throughout the manuscript. Intralipid vehicle was used as a control. The effect of Intralipid was examined at concentrations equivalent to those used for the propofol-Intralipid mixture.

Statistical analysis
--------------------

All Ca^2+^ imaging experimental protocols were repeated in a minimum of five separate coverslips of F-11 cells. Results obtained from each coverslip (for F-11 cell experiments) were averaged so that all coverslips of cells were weighted equally. Gaussian distribution was examined by the Shapiro--Wilk normality test. Comparisons between the groups were made using repeated-measures one-way analysis of variance and the Bonferroni post hoc test. Differences were considered statistically significant at *P *\<* *0.05. All results are expressed as mean ± SEM. The error bars in the figures refer to the variability in the peak of the Ca^2+^ response (Ca^2+^ imaging) or to the variability in intensity of the bands (immunoblot analysis) compared to the untreated control or a specific intervention, as noted in the legends. Statistical analysis was conducted using Sigma Plot 12.5 software (Systat Software, San Jose, CA).

Results
=======

Effect of PKC*ε* inhibition on AITC- and propofol-induced restoration of TRPV1 sensitivity to agonist stimulation in cultured TRPA1-TRPV1 co-transfectedF-11 cells
------------------------------------------------------------------------------------------------------------------------------------------------------------------

Individual F-11 cells containing both functional TRPV1 and TRPA1 receptors were first identified by treating the cells with single applications of capsaicin (100 nmol/L) and AITC (100 *μ*mol/L) a (Fig.[1A](#fig01){ref-type="fig"}). Repetitive stimulation of F-11 cells with capsaicin resulted in a progressive decrease (de-sensitization) in peak \[Ca^2+^\]~i~ (Fig.[1B](#fig01){ref-type="fig"}). When AITC (100 *μ*mol/L) was added to the bath during the 10 min pause in stimulation, subsequent reapplication of capsaicin resulted in a robust transient increase in \[Ca^2+^\]~i~ (resensitization) (Fig.[1B](#fig01){ref-type="fig"}). A similar resensitizing effect was observed with propofol (Fig.[1C](#fig01){ref-type="fig"}). Pretreatment with the PKC*ε*-specific inhibitory peptide *ε*V1--2 (0.5 *μ*mol/L) following desensitization inhibited the AITC- and propofol-induced restoration of TRPV1 sensitivity to capsaicin compared with F-11 cells treated only with propofol or AITC (Fig.[1D](#fig01){ref-type="fig"} and [E](#fig01){ref-type="fig"}). Summarized data depicting the effect of AITC and propofol alone or in the presence of *ε*V1--2 on restoration of TRPV1 sensitivity to capsaicin in TRPV1-TRPA1 cotransfected F-11 cells are depicted in Figure[1F](#fig01){ref-type="fig"}. Summarized results are expressed as a percent of the response to the final application of capsaicin in untreated cells (control).

![(A) Representative trace depicting the effect of a single application of the specific transient receptor potential vanilloid subtype-1 (TRPV1) agonist capsaicin (Cap; 100 nmol/L) and the specific transient receptor potential ankyrin receptor subtype-1 (TRPA1) activator allyl isothiocyanate (AITC, 100 *μ*mol/L) on intracellular free calcium concentration in F11 cells transfected with both TRPA1 and TRPV1 complementary DNA (cDNA). Representative traces depicting the effect of AITC (100 *μ*mol/L) alone, propofol (Prop, 10 *μ*mol/L) alone, AITC in the presence of specific PKC*ε* inhibitor *ε*V1--2 (0.5 *μ*mol/L), propofol in the presence of specific PKC*ε* inhibitor *ε*V1--2 after capsaicin-induced (100 nmol/L) desensitization on restoration of TRPV1 sensitivity in F-11 cells transfected with both TRPA1 and TRPV1 cDNA are depicted in Figure[1B](#fig01){ref-type="fig"}, C, D, and E, respectively. The *ε*V1--2 inhibitor peptide was added alone for 5 min following desensitization and then AITC or propofol was brought on board in combination with the *ε*V1--2 inhibitor peptide for an additional 5 min. Summarized data for Figure[1B](#fig01){ref-type="fig"}--[E](#fig01){ref-type="fig"} are depicted in Figure[1F](#fig01){ref-type="fig"}. Data are expressed as a percent of the response to the final application of capsaicin in the untreated control (% of control mean value ± SEM). \**P* \< 0.05 compared to final capsaicin in the untreated control. \#*P* \< 0.05 compared to AITC plus capsaicin. †*P* \< 0.05 compared to propofol plus capsaicin. *n = *seven separate coverslips of F-11 cells were used.](prp20003-e00153-f1){#fig01}

Effect of PKC*ε* activation on restoration of TRPV1 sensitivity to agonist stimulation in TRPV1 transfected F-11 cells
----------------------------------------------------------------------------------------------------------------------

F-11 cells containing only TRPV1 receptors were first identified by treating the cells with single applications of capsaicin (100 nmol/L) and AITC (100 *μ*mol/L). Cells that responded with a transient increase in \[Ca^2+^\]~i~ subsequent only to capsaicin were selected for the experiment (Fig.[2A](#fig02){ref-type="fig"}). Repetitive stimulation of F-11 cells with capsaicin resulted in a progressive decrease (desensitization) in peak \[Ca^2+^\]~i~ that was maintained following a 10-min pause in capsaicin stimulation as indicated by the lack of any response to capsaicin after reapplication of capsaicin to the bath (Fig.[2B](#fig02){ref-type="fig"}). In contrast, when the PKC*ε* activator peptide *ψε*RACK (0.5 *μ*mol/L) was added to the bath during the 10-min pause in stimulation, subsequent reapplication of capsaicin resulted in a robust transient increase in \[Ca^2+^\]~i~ (resensitization) (Fig.[2C](#fig02){ref-type="fig"}). Summarized data depicting the effect of *ψε*RACK (0.5 *μ*mol/L) on TRPV1 resensitization are depicted in Figure[2D](#fig02){ref-type="fig"}. Summarized results are expressed as a percent of the response to the final application of capsaicin during the initial desensitization of TRPV1.

![(A) Representative trace depicting the effect of a single application of capsaicin (100 nmol/L) and allyl isothiocyanate (AITC, 100 *μ*mol/L) on intracellular free calcium concentration inF-11 cells transfected with only functional transient receptor potential vanilloid receptor type 1 (TRPV1) receptors c-DNA. Representative traces depicting the effect of time and the protein kinase C epsilon (PKC*ε*) activator peptide (*Ψε*RACK, 0.5 *μ*mol/L) on restoration of TRPV1 sensitivity in F-11 cells containing only functional TRPV1 receptors (B and C). Summarized data for Figure[2C](#fig02){ref-type="fig"} are depicted in Figure[2D](#fig02){ref-type="fig"}. \**P* \< 0.05 compared to capsaicin-treated TRPV1-transfected F-11 cells. *n = *seven different cover slips containing TRPV1 transfected F-11 cells.](prp20003-e00153-f2){#fig02}

Effect of AITC and propofol on phosphorylation of PKC*ε* at S729 in cultured F11 cells expressing TRPV1 only or both TRPV1 and TRPA1
------------------------------------------------------------------------------------------------------------------------------------

To determine if the presence of TRPA1 receptors is required for propofol or AITC to activate PKC*ε* at S729, immunoblot analysis of PKC*ε*pS^729^ was performed before and after treatment of cells with either propofol (10 *μ*mol/L; 10 min), AITC (100 *μ*mol/L), or *ψε*RACK (0.5 *μ*mol/L). We also assessed the effect of the PKC*ε* inhibitor peptide, *ε*V1--2 (0.5 *μ*mol/L), on the propofol- and AITC-induced phosphorylation of S729. PKC*ε*pS^729^ levels were normalized to total PKC*ε* protein levels detected in the lysate. In TRPV1 transfectedF-11 cells, neither AITC (100 *μ*mol/L) nor propofol (10 *μ*mol/L) increased PKC*ε*pS^729^ levels as compared to untreated control (Fig.[3A](#fig03){ref-type="fig"}). However, treatment with the PKC*ε* activator peptide, *ψε*RACK (0.5 *μ*mol/L), increased PKC*ε*pS^729^ levels compared to control. In TRPV1-TRPA1 cotransfected F-11 cells, AITC, propofol, and *ψε*RACK all increased PKC*ε*pS^729^ levels compared to control (Fig.[3C](#fig03){ref-type="fig"}). Moreover, the AITC- and propofol-induced increases in PKC*ε*pS^729^ levels were prevented by pretreatment with the PKC*ε* inhibitory peptide, *ε*V1--2 in TRPV1-TRPA1 cotransfected F-11 cells (Fig.[3C](#fig03){ref-type="fig"}). In addition, following treatment with propofol (10 *μ*mol/L) or AITC (100 *μ*mol/L) in either cell type, the amount of immunodetectable PKC*ε* in the membrane fraction was unchanged as compared to untreated control (Fig.[3A](#fig03){ref-type="fig"} and [C](#fig03){ref-type="fig"}). The Intralipid (amount equivalent to 10 *μ*mol/L propofol) increased PKC*ε*pS^729^ levels to 127 ± 8% of control similar to our previous findings (Wickley et al. [@b36]). Summarized data for Figure[3A](#fig03){ref-type="fig"} and [C](#fig03){ref-type="fig"} are depicted in Figure[3B](#fig03){ref-type="fig"} and [D](#fig03){ref-type="fig"}, respectively.

![(A) Representative immunoblot depicting the effect of allyl isothiocyanate (AITC, 100 *μ*mol/L) alone, propofol (Prop, 10 *μ*mol/L) alone, the protein kinase C epsilon (PKC*ε*) activator peptide *Ψε*RACK (0.5 *μ*mol/L) alone, and AITC or propofol in the presence of the PKC*ε* inhibitor peptide *ε*V1--2 (0.5 *μ*mol/L) on PKC*ε* serine 729 phosphorylation (PKC*ε*pS^729^) in F-11 cells transfected with transient receptor potential vanilloid receptor type 1 (TRPV1) channels only. Total PKC*ε* was used as a loading control. (B) Summarized data for Figure[3A](#fig03){ref-type="fig"}. (C and D) Same as Figure[3A](#fig03){ref-type="fig"} and [B](#fig03){ref-type="fig"}, respectively, except in -11 cells transfected with both TRPV1 and transient receptor potential ankyrin receptor subtype-1 (TRPA1) channels. Data are expressed as a percent of the untreated control mean value ± SEM. \**P* \< 0.05 compared to control. \#*P* \< 0.05 compared to AITC alone. †*P* \< 0.05 compared to propofol alone. *n = *six different F-11 cell lysates.](prp20003-e00153-f3){#fig03}

Effect of propofol and AITC on TRPV1 phosphorylation at S800 in cultured F-11 cells expressing TRPV1 only or both TRPA1 and TRPV1
---------------------------------------------------------------------------------------------------------------------------------

To determine if the presence of TRPA1 receptors is required for propofol or AITC to phosphorylate TRPV1 at S800, immunoblot analysis of TRPV1pS^800^ was performed. TRPV1pS^800^ levels were normalized to total TRPV1 protein detected in the lysate. In TRPV1 transfected F-11 cells, neither AITC (100 *μ*mol/L) nor propofol (10 *μ*mol/L) increased TRPV1pS^800^ levels as compared to untreated control (Fig.[4A](#fig04){ref-type="fig"}). However, treatment with the PKC*ε* activator peptide, *ψε*RACK (0.5 *μ*mol/L), increased TRPV1pS^800^ levels compared to control. In TRPV1-TRPA1 cotrasfected F-11 cells, AITC, propofol, and *ψε*RACK all increased TRPV1pS^800^ levels compared to control (Fig.[4B](#fig04){ref-type="fig"}). Moreover, the AITC- and propofol-induced increases in TRPV1pS^800^ levels were prevented by pretreatment with the PKC*ε* inhibitory peptide, *ε*V1--2. In addition, following treatment with propofol (10 *μ*mol/L) or AITC (100 *μ*mol/L) in either cell type, the amount of immunodetectable TRPV1 in the cell lysate was unchanged as compared to untreated control (Fig.[4A](#fig04){ref-type="fig"} and [C](#fig04){ref-type="fig"}). The Intralipid vehicle had no detectable effect on TRPV1pS^800^ levels (103 ± 5% of control). Summarized data for Figure[4A](#fig04){ref-type="fig"} and [C](#fig04){ref-type="fig"} are depicted in Figure[4B](#fig04){ref-type="fig"} and [D](#fig04){ref-type="fig"}, respectively.

![(A) Representative immunoblot depicting the effect of allyl isothiocyanate (AITC, 100 *μ*mol/L) alone, propofol (Prop, 10 *μ*mol/L) alone, the protein kinase C epsilon (PKC*ε*) activator peptide *Ψε*RACK (0.5 *μ*mol/L) alone, and AITC or propofol in the presence of the PKC*ε* inhibitor peptide *ε*V1--2 (0.5 *μ*mol/L) on transient receptor potential vanilloid receptor type 1 (TRPV1) serine 800 phosphorylation (TRPV1pS^800^) in F-11 cells transfected with TRPV1 channels only. Total TRPV1 was used as a loading control. (B) Summarized data for Figure[4A](#fig04){ref-type="fig"}. (C and D) Same as Figure[4A](#fig04){ref-type="fig"} and [B](#fig04){ref-type="fig"}, respectively, except in F-11 cells transfected with both TRPV1 channels and transient receptor potential ankyrin receptor subtype-1 (TRPA1) channels. Data are expressed as a percent of the untreated control mean value ± SEM. \**P* \< 0.05 compared to control. \#*P* \< 0.05 compared to AITC alone. †*P* \< 0.05 compared to Prop alone. *n *= six different F-11 cell lysates.](prp20003-e00153-f4){#fig04}

Effect of NOS inhibition on propofol- and AITC-induced restoration of TRPV1 sensitivity
---------------------------------------------------------------------------------------

In F-11 cells transfected with both TRPV1 and TRPA1, inhibition of NOS with [l]{.smallcaps}-NG-nitroarginine methyl ester ([l]{.smallcaps}-NAME; 100 *μ*mol/L) prevented the propofol-induced restoration of TRPV1 sensitivity by more than 90% (Fig.[5B](#fig05){ref-type="fig"}). Moreover, the NO donor SNAP (100 *μ*mol/L) mimicked the effects of propofol on restoration of TRPV1 sensitivity (Fig.[5C](#fig05){ref-type="fig"}) and the restoring effect of SNAP was inhibited by the PKC*ε* inhibitor peptide (0.5 *μ*mol/L), *ε*V1--2 (Fig.[5D](#fig05){ref-type="fig"}). Similarly, the PKC*ε* activator peptide *ψε*RACK (0.5 *μ*mol/L) restored TRPV1 sensitivity in the presence of NOS inhibition with [l]{.smallcaps}-NAME (Fig.[5E](#fig05){ref-type="fig"}). Pretreatment with [l]{.smallcaps}-NAME alone did not restore sensitivity of TRPV1 to capsaicin (102 ± 9% of control). Summarized data for Figure[5A](#fig05){ref-type="fig"}--[E](#fig05){ref-type="fig"} are depicted in Figure[5F](#fig05){ref-type="fig"}.

![(A) Representative trace depicting the effect of propofol (Pro, 10 *μ*mol/L) alone, [l]{.smallcaps}-NG-nitroarginine methyl ester ([l]{.smallcaps}-NAME; 100 *μ*mol/L) plus propofol, *S*-nitroso-*N*-acetylpenicillamine (SNAP; 100 *μ*mol/L) alone, SNAP plus protein kinase C epsilon (PKC*ε*) inhibitor peptide *ε*V1--2 (0.5 *μ*mol/L), [l]{.smallcaps}-NAME plus the PKC*ε* activator peptide *Ψε*RACK (0.5 *μ*mol/L) after capsaicin-induced (100 nmol/L) desensitization on restoration of TRPV1 sensitivity to capsaicin (Cap) in mouse DRG neurons that contain functional TRPA1 and TRPV1 receptors are depicted in Figure[5A](#fig05){ref-type="fig"}, [B](#fig05){ref-type="fig"}, [C](#fig05){ref-type="fig"} and [D](#fig05){ref-type="fig"} and [E](#fig05){ref-type="fig"}, respectively. The NOS inhibitor [l]{.smallcaps}-NAME was added alone for 5 min following desensitization and then propofol or the PKC*ε* activator peptide *Ψε*RACK were brought on board in combination with [l]{.smallcaps}-NAME for an additional 5 min. Similarly, the *ε*V1--2 inhibitor peptide was added alone for 5 min following desensitization and then SNAP was brought on board in combination with the *ε*V1--2 inhibitor peptide for an additional 5 min. Summarized data for Figure[5A](#fig05){ref-type="fig"}--[E](#fig05){ref-type="fig"} are depicted in Figure[5F](#fig05){ref-type="fig"}. Data are expressed as a percent of the response to the final application of capsaicin in the untreated control (% of control mean value ± SEM). \**P* \< 0.05 compared to final capsaicin in the untreated control. \#*P* \< 0.05 compared to Pro plus capsaicin. †*P* \< 0.05 compared to SNAP plus capsaicin. *n *= F-11 cells from seven separate cover slips.](prp20003-e00153-f5){#fig05}

Effect of NOS inhibition on propofol- and AITC-induced PKC*ε* phosphorylation at S729 in cultured F-11 cells expressing both TRPA1 and TRPV1
--------------------------------------------------------------------------------------------------------------------------------------------

In F-11 cells transfected with TRPA1 and TRPV1, pretreatment with the NO donor, SNAP, increased immunodetectable phosphorylation of PKC*ε*pS^729^ (Fig.[6A](#fig06){ref-type="fig"}). Moreover, inhibition of NOS with [l]{.smallcaps}-NAME prevented the propofol- and AITC-induced increase in immunodetectable PKC*ε*pS^729^. Incubation with [l]{.smallcaps}-NAME alone had no significant effect on basal levels of PKC*ε*pS^729^ (98 ± 8% of control). Summarized data for Figure[6A](#fig06){ref-type="fig"} are depicted in Figure[6B](#fig06){ref-type="fig"}.

![(A) Representative immunoblot depicting the effect of allyl isothiocyanate (AITC, 100 *μ*mol/L) alone, propofol (Prop, 10 *μ*mol/L) alone, *S*-nitroso-*N*-acetylpenicillamine (SNAP; 100 *μ*mol/L), propofol in the presence of the NOS inhibitor, [l]{.smallcaps}-NG-nitroarginine methyl ester ([l]{.smallcaps}-NAME; 100 *μ*mol/L) or allyl isothiocyanate (AITC, 100 *μ*mol/L) in the presence of [l]{.smallcaps}-NAME on PKC*ε* serine 729 phosphorylation (PKC*ε*pS^729^) in F-11 cells transfected with both TRPV1 and TRPA1. Total PKC*ε* was used as a loading control. (B) Summarized data for Figure[6A](#fig06){ref-type="fig"}. Data are expressed as a percent of the untreated control mean value ± SEM. \**P* \< 0.05 compared to control. \#*P* \< 0.05 compared to AITC alone. †*P* \< 0.05 compared to Prop alone. *n *= six different F-11 cell lysates.](prp20003-e00153-f6){#fig06}

Effect of propofol and AITC on phosphorylation of NOS at Ser1417 and on NO production in cultured F-11 cells expressing both TRPA1 and TRPV1
--------------------------------------------------------------------------------------------------------------------------------------------

No significant change in the expression level of nNOS was observed in nontransfected, TRPV1-trasfected, TRPA1-transfected, and TRPV1-TRPA1 cotransfected F-11 cells (Fig.[7A](#fig07){ref-type="fig"}). However, TRPV1--TRPA1 cotransfected F-11 cells pretreated with propofol (10 *μ*mol/L) and AITC (100 *μ*mol/L) demonstrated increased phosphorylation of nNOS at Ser^1417^ compared to the nontreated cells lysate, that was significantly attenuated by the TRPA1 antagonist, HC-030031 (0.5 *μ*mol/L; Fig.[7B](#fig07){ref-type="fig"}). Summarized data for Figure[7B](#fig07){ref-type="fig"} are depicted in Figure[7C](#fig07){ref-type="fig"}. AITC (100 *μ*mol/L) - and propofol (10 *μ*mol/L) -induced NO production was also detected and visualized in TRPV1-TRPA1 cotransfected F-11 cells, that was mimicked by SNAP (100 *μ*mol/L). Moreover, propofol-induced NO production was attenuated in presence of HC-030031 (0.5 *μ*mol/L). Changes in intracellular NO production were compared to cells pretreated with [l]{.smallcaps}-Arginine, an NO inducer (100 *μ*mol/L), and c-PTIO, an NO scavenger (10 *μ*mol/L) (Fig.[7](#fig07){ref-type="fig"}).

![(A) Representative immunoblot depicting the expression of nNOS in nontransfected F-11 cells (F-11 NT), TRPV1-transfected F-11 cells (F-11 V1), TRPA1-transfected F-11 cells (F-11 A1), and TRPV1-TRPA1 co-transfected F-11 cells (F-11 V1/A1). GAPDH was used as a loading control. (B) Represents the effect of allyl isothiocyanate (AITC, 100 *μ*mol/L) alone, propofol (Prop, 10 *μ*mol/L) alone, and propofol in presence of HC-030031 (0.5 *μ*mol/L) on nNOS serine 1417 phosphorylation (nNOSS^1417^) in F-11 cells transfected with both TRPV1 and TRPA1. Total nNOS was used as a loading control. (C) Summarized data for Figure[7B](#fig07){ref-type="fig"}. (D) Representative fluorescence images depicting the effect of [l]{.smallcaps}-Arginine (NO-inducer), c-PTIO (NO scavenger), AITC (100 *μ*mol/L), propofol (10 *μ*mol/L), SNAP (100 *μ*mol/L), and propofol in the presence of HC-030031(0.5 *μ*mol/L) on NO production in TRPA1 and TRPV1 cotransfected F-11 cells. Data are expressed as a percent of the untreated control mean value ± SEM. \**P* \< 0.05 compared to control. *n *= six different F-11 cell lysates.](prp20003-e00153-f7){#fig07}

Discussion
==========

This is the first study to delineate the role of PKC*ε* in TRPA1-dependent restoration of TRPV1 sensitivity as well as to determine the mechanism by which TRPA1 activates PKC*ε*. We previously demonstrated that propofol restores TRPV1 sensitivity via a PKC*ε*-dependent phosphorylation of the channel (Wickley et al. [@b36]) and is dependent on the presence of functional TRPA1 receptors (Zhang et al. [@b38]). However, the extent to which propofol activates these two pathways independently and in parallel or whether they are directly linked to one another via an unknown signaling pathway has not been established. Our key findings are that the AITC and propofol-induced restoration of TRPV1 sensitivity are mediated by a TRPA1-dependent activation of PKC*ε* Moreover, TRPA1-induced activation of PKC*ε* is mediated via a NOS-dependent pathway.

Our first objective was to determine the whether activation of PKC*ε* is directly linked to TRPA1-dependent restoration of TRPV1 sensitivity. Our current results substantiate our previous findings that inhibition of PKC*ε* prevents the propofol-induced restoration of TRPV1 sensitivity (Wickley et al. [@b36]) and our current novel findings indicate that the PKC*ε* inhibition also prevents the AITC-induced restoration of TRPV1 sensitivity to agonist stimulation. These data are also consistent with previous findings demonstrating increased sensitivity of desensitized TRPV1 by phorbol esters occurs through PKC*ε*-mediated phosphorylation of TRPV1 (Mandadi et al. [@b21]).

Although our results indicate that PKC*ε* is required for TRPA1 activation to restore TRPV1 sensitivity, indicating a TRPA1-dependent activation of PKC*ε*, these results do not conclusively rule out the possibility that PKC*ε* may activate TRPA1 and subsequently restore TRPV1 sensitivity. Therefore, we assessed the effect of the PKC*ε*-specific activator peptide, *ψε*RACK, on restoration of TRPV1 sensitivity in F-11 cells expressing only TRPV1. Our findings indicate that direct activation of PKC*ε* does not require the presence of TRPA1 receptors in order to restore TRPV1 sensitivity, and that TRPA1 stimulation is upstream of PKC*ε* activation. Our current findings are similar to a previous study indicating that PKC*ε* acts downstream of bradykinin and is principally responsible for sensitization of the heat response in nociceptors by bradykinin (Cesare et al. [@b10]).

As part of the activation process, PKC*ε* is autophosphorylated at S729 rendering it catalytically competent. Our results indicate that in cells containing TRPV1 and TRPA1, propofol and AITC phosphorylate PKC*ε* at S729. This effect was markedly attenuated in F-11 cells containing only TRPV1 indicating that propofol primarily activates PKC*ε* via a TRPA1-dependent pathway. It should be noted that in addition to the important role of PKC*ε* in TRPV1 regulation, there may also be a direct molecular interaction between TRPA1 and TRPV1 that operates in parallel (Ruparel et al. [@b30]; Salas et al. [@b31]; Staruschenko et al. [@b34]; Akopian [@b1]).

The PKC*ε*-dependent phosphorylation of TRPV1 at S800 has been shown to increase the sensitivity of TRPV1 to agonist stimulation (Zhou et al. [@b39]; Mandadi et al. [@b21]; Srinivasan et al. [@b33]). In the current study, we now demonstrate that TRPA1 is required for propofol or AITC to phosphorylate TRPV1 at S800 indicating a TRPA1-dependent signaling cascade leading to activation of PKC*ε* and subsequent phosphorylation of TRPV1 at S800. We previously demonstrated that the propofol increased TRPV1pS^800^ and that this increase was not observed in sensory neurons derived from PKC*ε*^−/−^ mice (Wickley et al. [@b36]).

Previous studies in other cell types have indicated that NO donors are capable of activating specific PKC isoforms (Burgstahler and Nathanson [@b8]; Liang and Knox [@b18]; Harada et al. [@b13]; Lee et al. [@b16]) including PKC*ε* (Nishio and Watanabe [@b24]; Ping et al. [@b27]; Bolli [@b5]; Balafanova et al. [@b4]). In our study, NOS inhibition prevented the agonist-induced restoration of TRPV1 sensitivity. Moreover, the NO donor SNAP restored TRPV1 sensitivity, an effect that was abolished by PKC*ε* inhibition and NOS inhibition failed to prevent restoration of TRPV1 sensitivity by the PKC*ε* activator peptide. These data suggest that NO is a mediator of the TRPA1-dependent restoration of TRPV1 sensitivity and are consistent with a TRPA1-dependent induction of hyperthermia in rats which was dependent on NO production suggesting TRPA1 stimulates NOS activation (Ding et al. [@b12]).

Some studies have demonstrated that NO donors can directly activate TRP channels causing increases in intracellular Ca^2+^ (Yoshida et al. [@b37]; Miyamoto et al. [@b23]). In our study, we saw no increase in intracellular Ca^2+^ upon application of SNAP in cells transfected with both channels. This may be due to the significantly lower concentration of SNAP (100 *μ*mol/L) used in our study compared to others using concentrations between 1 and 5 mmol/L (Miyamoto et al. [@b23]).

In order to biochemically determine the extent to which TRPA1 activation is linked to NO production and activation of PKC*ε*, we utilized F-11 cells transfected with both channels. In these studies, NOS inhibition with [l]{.smallcaps}-NAME prevented the agonist-induced increase in immunodetectable PKC*c*pS^729^. Moreover, SNAP stimulated an increase in immunodetectable PKC*ε*pS^729^. These data are consistent with the Ca^2+^ imaging data indicating a TRPA1-dependent activation of NOS leading to NO-dependent phosphorylation of PKC*ε* and restoration of TRPV1 sensitivity. The precise mechanism by which NO causes PKC*ε* activation is not known but several possibilities exist. NO reacts with superoxide anions to form peroxynitrite that can activate PKC (Reiter et al. [@b29]; Chakraborti et al. [@b11]; Li et al. [@b17]). Alternatively, the NO donor effect enhances PKC interaction with its specific anchor protein RACK2 via nitration of tyrosine residues of PKC, resulting in its activation (Balafanova et al. [@b4]).

This study also investigated the role of agonist-induced TRPA1 activation in activating nNOS and regulation of NO production in TRPV1 and TRPA1 coexpressing cells. Our data suggest that activation of TRPA1 leads to increased phosphorylation of nNOS at serine 1417 as well as NO production that is substantially attenuated in the presence of the TRPA1 antagonist, HC-030031. There were no significant changes in nNOS expression in any of the groups. These data further support the role of nNOS in TRPA1-mediated restoration of TRPV1 sensitivity and also confirms that nNOS is downstream of TRPA1.

Overall, our current findings are consistent with previous studies indicating cross talk between TRPV1 and TRPA1 receptors which regulate and modulate nociceptive ion channel function (Brand and Jacquot [@b7]; Akopian et al. [@b2]; Salas et al. [@b31]; Simons et al. [@b32]). Moreover, our data indicating TRPA1-dependent activation of NOS, leading to PKC*ε* activation and subsequent restoration of TRPV1 sensitivity provides new evidence needed to elucidate the mechanisms by which TRPA1 and TRPV1 regulate each other's function. A summary of the proposed cellular signaling pathway by which cross talk between TRPA1 and TRPV1 channels occurs is depicted in Figure[8](#fig08){ref-type="fig"}. The contribution of TRPV1 and TRPA1 to peripheral nociception supports the idea that one approach to control peripheral nociception is to better understand and manage cross regulation between TRPV1 and TRPA1 channels. A better understanding of these intricate mechanisms could prove vital in the search for therapeutic strategies to treat pathological conditions involving altered nociceptive processes.

![Schematic diagram depicting the proposed signaling pathway for cross talk between TRPA1 and TRPV1 ion channels (depicted by black arrows). Capsaicin (TRPV1 agonist); propofol and allyl isothiocyanate (AITC; TRPA1 agonists); HC-030031 (TRPA1 antagonist; [l]{.smallcaps}-NAME (neuronal nitric oxide synthase (nNOS) antagonist); NO (nitric oxide); SNAP (NO donor); protein kinase C epsilon (PKC*ε*); *Ψε*RACK (PKC*ε* activator peptide); *ε*V1--2 (PKC*ε* inhibitor peptide).](prp20003-e00153-f8){#fig08}

TRPA1 and TRPV1 cDNA were provided by David Julius, Ph.D., Professor, Department of Physiology, University of California at San Francisco. F-11 cells were gift from Probal Banerjee, Ph.D., Professor, Department of Chemistry, College of Staten Island, New York. Serine 800 phospho-TRPV1 antibody was provided by M.Tominaga, Division of Cell Signaling, Okazaki Institute for Integrative Biosciences (National Institute for Physiological Sciences), Japan.

Author Contributions
====================

Zhang, Sinharoy, Sinha, Bratz, Damron participated in research design and performed the data analysis. Zhang, Sinharoy, Prudner conducted the experiments. Damron, Sinharoy, and Sinha wrote or contributed to the writing of the manuscript.

Disclosure
==========

None declared.

AITC

:   allyl isothiocyanate

c-PTIO

:   2-4-carboxyphenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide

[l]{.smallcaps}-NAME

:   [l]{.smallcaps}-NG-nitroarginine methyl ester

NO

:   nitric oxide

NOS

:   nitric oxide synthase

PKC*ε*

:   protein kinase C epsilon

RACK
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SNAP

:   *S*-nitroso-*N*-acetyl-[d]{.smallcaps},[l]{.smallcaps}-penicillamine

TRPA1

:   transient receptor potential ankyrin channel subtype-1

TRPV1

:   transient receptor potential vanilloid channel subtype-1
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